Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 2/20 | 1.00 |
| ▸ | PRKAA1 | Q13131 | 7/20 | 0.70 |
| ▸ | PRKAA2 | P54646 | 6/20 | 0.70 |
| ▸ | PDGFRB | P09619 | 11/20 | 0.69 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.69 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.69 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.69 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.69 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.69 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.69 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.69 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.69 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.69 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.69 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.69 |
| ▸ | KDR | P35968 | 10/20 | 0.69 |
| ▸ | TLK2 | Q86UE8 | 3/20 | 0.69 |
| ▸ | FGFR1 | P11362 | 7/20 | 0.68 |
| ▸ | FLT1 | P17948 | 2/20 | 0.68 |
| ▸ | PLK4 | O00444 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL859965 | 1.00 | ALK (1.00) | ALKPRKAA1PRKAA2PDGFRBHDAC3 | |
| SCHEMBL6587955 | 0.91 | ALK (0.83) | ALKPRKAA1PRKAA2PDGFRBHDAC3 | |
| SCHEMBL3268874 | 0.91 | ALK (0.83) | ALKPRKAA1PRKAA2PDGFRBHDAC3 | |
| SCHEMBL8210235 | 0.91 | ALK (0.83) | ALKPRKAA1PRKAA2PDGFRBHDAC3 | |
| SCHEMBL4149397 | 0.90 | ALK (0.81) | ALKPRKAA1PRKAA2PDGFRBHDAC3 | |
| SCHEMBL27919661 | 0.90 | ALK (0.81) | ALKPRKAA1PRKAA2PDGFRBHDAC3 | |
| SCHEMBL12329173 | 0.90 | ALK (0.82) | ALKPRKAA1PRKAA2PDGFRBHDAC3 | |
| SCHEMBL30733142 | 0.90 | ALK (0.82) | ALKPRKAA1PRKAA2PDGFRBHDAC3 | |
| SCHEMBL17503076 | 0.90 | ALK (0.82) | ALKPRKAA1PRKAA2PDGFRBHDAC3 | |
| SCHEMBL29486525 | 0.90 | ALK (0.82) | ALKPRKAA1PRKAA2PDGFRBHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 248 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200163877-A1 | LIPOSOME FORMULATIONS | OPKO PHARMACEUTICALS, LLC. | 2020-05-28 | — | — | US | claimed |
| CN-109485639-B | Preparation method of sunitinib | 石药集团中奇制药技术（石家庄）有限公司 | 2020-04-07 | — | — | CN | claimed |
| US-20190321467-A1 | LIPOSOME FORMULATIONS | OPKO PHARMACEUTICALS, LLC. | 2019-10-24 | — | — | US | claimed |
| EP-2828251-B1 | AN IMPROVED PROCESS FOR THE PREPARATION OF SUNITINIB AND ITS ACID ADDITION SALTS THEREOF | LAURUS LABS LTD (IN) | 2018-10-31 | — | — | EP | claimed |
| US-9206163-B2 | Process for the preparation of sunitinib and its acid addition salts thereof | LAURUS LABS PRIVATE LTD. (IN) | 2015-12-08 | — | — | US | claimed |
| US-20150224055-A1 | LIPOSOME FORMULATIONS | OPKO PHARMACEUTICALS, LLC | 2015-08-13 | — | — | US | claimed |
| EP-2828251-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF SUNITINIB AND ITS ACID ADDITION SALTS THEREOF | Laurus Labs Private Limited (IN) | 2015-01-28 | — | — | EP | claimed |
| US-20150025252-A1 | PROCESS FOR THE PERPARATION OF SUNITINIB AND ITS ACID ADDITION SALTS THEREOF | LAURUS LABS LIMITED (IN) | 2015-01-22 | — | — | US | claimed |
| WO-2013140232-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF SUNITINIB AND ITS ACID ADDITION SALTS THEREOF | LAURUS LABS PRIVATE LIMITED (IN) | 2013-09-26 | — | — | WO | claimed |
| US-20110293615-A1 | Use of Combination of Anti-Angiogenic Substance and c-kit Kinase Inhibitor | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-12-01 | — | — | US | claimed |
| US-7125905-B2 | Pyrrole substituted 2-indolinone protein kinase inhibitors | AGOURON PHARMACEUTICALS, INC. (US) | 2006-10-24 | — | — | US | claimed |
| EP-1696906-A1 | NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES | Leo Pharma A/S (DK) | 2006-09-06 | — | — | EP | claimed |
| US-20060135486-A1 | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors | EISAI CO., LTD. (JP) | 2006-06-22 | — | — | US | claimed |
| US-20050176802-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. & PHARMACIA & UPJOHN CO. | 2005-08-11 | — | — | US | claimed |
| WO-2005058309-A1 | NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES | LEO PHARMA A/S (DK) | 2005-06-30 | — | — | WO | claimed |
| US-20040018528-A1 | Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals | SUGEN, INC. | 2004-01-29 | — | — | US | claimed |
| EP-1370554-A1 | 3-(4-AMIDOPYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PHARMACIA & UPJOHN COMPANY (US) | 2003-12-17 | — | — | EP | claimed |
| WO-2003097854-A2 | NOVEL BIOMARKERS OF TYROSINE KINASE INHIBITOR EXPOSURE AND ACTIVITY IN MAMMALS | SUGEN, INC. (US) | 2003-11-27 | — | — | WO | claimed |
| US-6653308-B2 | Anticancer agents; antidiabetic agents; antiinflammatory agents | SUGEN, INC. | 2003-11-25 | — | — | US | claimed |
| WO-2002066463-A1 | 3-(4-AMIDOPYRROL-2-YLMETHLIDENE)-2-INDOLINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PHARMACIA & UPJOHN COMPANY (US) | 2002-08-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176802-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | PDPK1, MAP3K20, PLK2 | ALK 1177/4885PRKAA1 75/4885PRKAA2 99/4885 |
| US-20060135486-A1 | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors | FLT4, KDR, FLT1 | ALK 523/4885PRKAA1 4268/4885PRKAA2 4027/4885 |
| US-20110293615-A1 | Use of Combination of Anti-Angiogenic Substance and c-kit Kinase Inhibitor | KIT, FLT4, KDR | ALK 167/4885PRKAA1 632/4885PRKAA2 620/4885 |
| US-20150025252-A1 | PROCESS FOR THE PERPARATION OF SUNITINIB AND ITS ACID ADDITION SALTS THEREOF | SUN2, FGFR3, FGFR4 | ALK 1754/4885PRKAA1 1808/4885PRKAA2 1580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.